

Curriculum Vitae

Robyn E. Elmslie
Veterinary Cancer Specialists
3550 S Jason Street
Englewood, CO 80110

POSITIONS:

1993 to present: Owner and Director, Veterinary Cancer Specialists, Englewood, CO
1990-1993: NIH Post-Doctoral Fellow, National Jewish Medical Center, Denver, CO
1987-1990: Oncology Residency, Colorado State University, Ft. Collins, CO

EDUCATION AND TRAINING:

1982-1986. Doctorate of Veterinary Medicine, School of Veterinary Medicine, University of Montreal, St-Hyacinthe, Quebec, Canada
1986-1987. Internship in small animal medicine and surgery. School of Veterinary Medicine. University of Montreal. St-Hyacinthe, Quebec, Canada
1987-1988. Clinical Instructor in Small Animal Medicine. School of Veterinary. Medicine. University of Montreal. St-Hyacinthe, Quebec, Canada.
1988-1990. Residency in Clinical Oncology. Veterinary Teaching Hospital. Colorado State University, CO, USA
1990-1993. Post-Doctoral Fellow in Immunology, (laboratory of Dr. Edward Palmer), National Jewish Center for Immunology and Respiratory Medicine, Denver, Colorado.

Board Certification: 1992; Diplomate, ACVIM (Oncology)

PROFESSIONAL ACTIVITIES:

Memberships in professional societies:

American Veterinary Medical Association
Veterinary Cancer Society
American College of Veterinary Internal Medicine
Denver Area Veterinary Medical Society

Committees and Review Boards:

1. ACVIM, Oncology exam committee: 1995-1996.
2. ACUC committee; 1994-1995; Swedish Hospital, Englewood, CO
3. ACUC committee; 2000-present; Veterinary Referral Center of Colorado; Englewood, CO
4. VRCC Governance Board (1993 to present), Veterinary Referral Center of Colorado

SCHOLARLY ACTIVITIES:

Peer-Reviewed Publications:

1. Elmslie RE, Dow SW, Ogilvie GK. Interleukins; biological activities and clinical applications. *J. Vet. Int. Med.* 1991; 5:283-293.
2. Elmslie RE, Ogilvie GK, Dow SW, et al. Evaluation of a biological response modifier derived from *Serratia marcescens*: effects on feline macrophages and usefulness for the prevention and treatment of viremia in FeLV-infected cats. *J. Mol Biother.* 1991; 3:231-238.

3. Elmslie RE, Ogilvie GK, Gillette EL, et al. Radiotherapy with and without chemotherapy for the control of localized lymphoma in cats: 10 cases (1983-1989). *Vet Radiol*. 1991; 32(6):277-280.
4. Ogilvie GK, Obradovich J, Elmslie RE, et al. Toxicosis associated with the administration of mitoxantrone to dogs with malignant tumors. *J Am Vet Med Assoc*. 1991; 198:1613-1617.
5. Ogilvie GK, Obradovich J, Elmslie RE, et al. Phase II evaluation of mitoxantrone against various canine neoplasms. *J Am Vet Med Assoc*. 1991; 198:1618-1621.
6. Ogilvie GK, Elmslie RE, Cecchini, et al. The use of a biological extract of *Serratia marcescens* to decrease doxorubicin-induced myelosuppression in the dog. *Am J Vet Res*. 1992; 53(10):1787-90.
7. Ogilvie GK, Moore AS, Obradovich JE, Elmslie RE, et al. (1993) Toxicoses and efficacy associated with the administration of mitoxantrone to cats with malignant tumors. *J Am Vet Med Assoc* 202 (11):1839-44.
8. Elmslie RE and Dow SW. (1997) Genetic immunotherapy for cancer. *Seminar Vet Med Surg* 12:193-205.
9. Elmslie RE, Willson AP, Roche L, Gorman C, and Potter TA. (1998) Superantigen plus cytokine gene therapy induces tumor regression and prolongs survival in dogs with malignant melanoma. *J Clin Invest* 101:2406-2414
10. Dow SW, Elmslie RE, Fradkin L, Liggitt D, Willson AP, Heath TH, Potter TA. (1999). Systemic injection of DNA-lipid complexes and IL-2 or IL-12 genes controls the growth of established lung tumor metastases. *Hu Gene Ther* 10:2961-2972.
11. Walsh P, Gonzalez R, Dow S, Elmslie R, Potter T, Glode LM, Baron AE, Balmer C, Easterday K, Allen J, Rosse P. A phase I study using direct combination DNA injections for the immunotherapy of metastatic melanoma. University of Colorado Cancer Center Clinical Trial. *Hum Gene Ther*. 2000 Jun 10;11(9):1355-68.
12. Dow S, Elmslie R, Kurzman I, McEwen G, Pericle F, and Liggitt D. (2005) Phase I study of liposome-nucleic acid complexes encoding the IL-2 gene for treatment of canine osteosarcoma metastases. *Hu Gene Ther* 16:937-946.
13. Kamstock D, Guth A, Elmslie R, Kurzman I, Fairman J, Coro L, and Dow S. (2006). Liposome-DNA complexes infused intravenously inhibit tumor angiogenesis and elicit antitumor activity in dogs with soft tissue sarcoma. *Cancer Gene Therapy* 13, 306-317.
14. U'Ren L, Biller B, Elmslie R, Thamm D, and Dow S. Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma. *J Vet Intern Med*, under revision, 2006.

Book Chapters:

1. Elmslie RE and Dow SW. Gene therapy of cancer. In, Current Veterinary Therapy, XVIII, WB Saunders, 1999.
2. Elmslie RE, Ogilvie GK. Solitary Extranodal lymphomas: presentation and management. In Consultations in Feline Internal Medicine. August JR ed. WB Saunders Co. 1994 Philadelphia, pp 547-552.
3. Elmslie RE, Ogilvie GK. Variables in behavior and management of mast cell tumors. In Consultations in Feline Internal Medicine. August JR ed. WB Saunders Co. 1994 Philadelphia, pp 567-572.
4. Elmslie RE. Cutaneous Hemangiosarcoma. In The 5-Minute Veterinary Consult, Clinical Companion, Small Animal Dermatology. Lippincott Williams and Wilkins, 2002.
5. Elmslie RE. Mast Cell Tumors. In The 5-Minute Veterinary Consult, Clinical Companion, Small Animal Dermatology. Lippincott Williams and Wilkins, 2002.
6. Elmslie RE. Basal Cell Tumor. In The 5-Minute Veterinary Consult, Clinical Companion, Small Animal Dermatology. Lippincott Williams and Wilkins, 2002.
7. Elmslie RE. Adenocarcinoma, Skin (Sweat gland, sebaceous). In The 5-Minute Veterinary Consult, Clinical Companion, Small Animal Dermatology. Lippincott Williams and Wilkins, 2002.
8. U'Ren L, Elmslie R, and Dow S. Gene therapy for cancer. In Current Veterinary Therapy, in preparation, 2006.

Abstracts, Seminars, Continuing Education

1. Immunotherapy for canine cancer; ACVIM Annual Forum, May, 1994.
2. Superantigen gene therapy for canine melanoma. Vet Cancer Society annual meeting; Oct, 1997
3. Systemic cytokine gene therapy for pulmonary metastatic cancer. Vet Cancer Soc annual meeting, Oct 1998.
4. Novel approach to intravenous DNA vaccination for canine tumors. Vet Cancer Society annual meeting, Oct, 2000.
5. Evaluation of the angiogenesis inhibiting effects of intravenous gene therapy in dogs with soft tissue sarcoma; Veterinary Cancer Society, Oct, 2001
6. Clinical oncology updates; VRCC Continuing Education Series for Denver area veterinarians, annually or twice annually since 1995.

CURRENT RESEARCH:

1. Evaluation of a novel TK inhibitor for treatment of canine mast cell tumors; 2004 to present; AB Science; Co-investigator
2. Vaccination with xenogeneic VEGF for inhibition of angiogenesis in dogs with soft tissue sarcoma; 2004 to present; NIH; Co-Investigator
3. Antiangiogenic therapy for dogs with measureable soft tissue sarcomas. 2005-present; Animal Clinical Investigation, LLC; Co-Investigator.

PAST RESEARCH

1. Superantigen gene therapy for dogs with melanoma. 1996-1998; Colorado Cancer League; Co-Investigator
2. Intravenous IL-2 gene therapy for osteosarcoma metastases in dogs. 1999-2003; Morris Animal Foundation; Co-Investigator
3. Combination chemotherapy and IL-2 gene therapy for metastatic cancer in dogs. 1999-2000; Valentis Corporation; Principal investigator
4. Systemic endostatin gene therapy for soft tissue sarcoma in dogs. 1999-2004, Morris Animal Foundation; Co-Investigator
5. Evaluation of a matrix metalloproteinase inhibitor in dogs with lymphoma and osteosarcoma; 1997-1999; Bayer Corporation; Co-Investigator
6. Allogeneic tumor vaccine for canine melanoma; 2001-2004; NIH, Co-Investigator
7. Endothelial cell vaccine for canine hemangiosarcoma; 2001-2003; NIH, Co-Investigator
8. Evaluation of TSP-1 as an anti-angiogenic agent in dogs; 2002-2003; Abbott Laboratories; Co-investigator

COMMUNITY ACTIVITIES:

1. Member, Animal Care Foundation; Denver, CO; 1999- 2003.
2. Board of Directors, Montessori School at Ken-Caryl; Member: 2003; Chairman, 2004 to 2005
3. Littleton Soccer League; Parent Coordinator; 2003-present